100 help plan
The good news over the weekend is that the two parties in the United States have reached a preliminary agreement on the debt ceiling, which means that they are finally aware of the consequences of default. For Biden in particular, he also hopes to be re-elected, and in the event of a default, he will become the first United States to default in 200 years**, which will cause great damage to his reputation.
The confirmation of this news has removed the uncertainty of the external market and brought some positive news to people. U.S. stocks soared on Friday, with the Nasdaq hitting a new high!The world has been **recently**, only A-shares and Hong Kong stocks have been**, this comparison is really sad. It seems that foreigners will only chase high, and we are in the trough.
The resolution of the U.S. debt problem, as well as the meeting between the Chinese and U.S. commerce ministers, are positive signs. U.S. stocks have already risen a lot, and it would be too timid to fall again next week. Of course, there is no shortage of opportunities for local speculation in A-shares, such as U.S. semiconductors, especially Nvidia's share price, which has hit a new high, which has brought great stimulation to A-shares. Next week, popular concept stocks such as computing power, COP and other technology sectors will continue to hype again.
Tianpu shares: plans to increase the total capital of the two subsidiaries by 3300 million yuan to improve the company's overall strategic layout.
Sichuan Investment Energy plans to invest 826.3 billion yuan Set up a project company to invest in the development of Yibin Pingshan pumped storage power station.
Yabao Pharmaceutical has repurchased a total of 234% of the shares cost about 1$2.8 billion.
Hengrui Pharmaceutical's subsidiary obtained a drug registration certificate.
High Energy Environment received an increase of 110,000 shares from two directors.
Publishing Media elected Zhang Dongping as chairman.
Rongtai Health: Carry out shareholder feedback activities.
Kindike's quadrivalent influenza vaccine for the 2023-2024 influenza season was approved for issuance.
The content of the article belongs to the collation and statistics of public information, and does not constitute a recommendation or any basis for buying and selling.